TP1 Antibody is affinity chromatography purified via peptide column.
Immunogen
TP1 antibody was raised against a 20 amino acid synthetic peptide from near the amino terminus of human TP1. The immunogen is located within the first 50 amino acids of TP1.
TNP1
Reactivity: Human
WB, IF (cc), IF (p)
Host: Rabbit
Polyclonal
AbBy Fluor® 350
Application Notes
TP1 antibody can be used for detection of TP1 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
TP1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
TP1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TNP1
(Transition Protein 1 (During Histone To Protamine Replacement) (TNP1))
TP1 Antibody: Telomerase is an RNA-dependent DNA polymerase that uses an RNA component to add telomeric repeat sequences at the ends of chromosomes. Besides the RNA component which serves as the template that specifies the telomeric repeat, the telomerase complex contains a reverse transcriptase protein (TRT) and various accessory proteins including the telomerase-associated protein 1 (TP1). Telomerase activity is low in most somatic cells, causing the gradual shortening of telomeres which can ultimately lead to telomere fusion and cell death. High levels of telomerase activity are widely seen in cancerous cells and while recent experiments have suggested that telomerase may be a viable target in cancer therapy, expression levels of TP1 do not correlate with malignancy. At least two isoforms of TP1 are known to exist.